JP2025516649A5 - - Google Patents
Info
- Publication number
- JP2025516649A5 JP2025516649A5 JP2024566593A JP2024566593A JP2025516649A5 JP 2025516649 A5 JP2025516649 A5 JP 2025516649A5 JP 2024566593 A JP2024566593 A JP 2024566593A JP 2024566593 A JP2024566593 A JP 2024566593A JP 2025516649 A5 JP2025516649 A5 JP 2025516649A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- compound
- combination according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341361P | 2022-05-12 | 2022-05-12 | |
| US63/341,361 | 2022-05-12 | ||
| PCT/US2023/066920 WO2023220703A1 (en) | 2022-05-12 | 2023-05-12 | Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516649A JP2025516649A (ja) | 2025-05-30 |
| JP2025516649A5 true JP2025516649A5 (enExample) | 2026-05-20 |
Family
ID=86710772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566593A Pending JP2025516649A (ja) | 2022-05-12 | 2023-05-12 | Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250312339A1 (enExample) |
| EP (1) | EP4522173A1 (enExample) |
| JP (1) | JP2025516649A (enExample) |
| KR (1) | KR20250012585A (enExample) |
| CN (1) | CN119183377A (enExample) |
| AR (1) | AR129314A1 (enExample) |
| AU (1) | AU2023269154B2 (enExample) |
| CA (1) | CA3248752A1 (enExample) |
| TW (1) | TW202408523A (enExample) |
| WO (1) | WO2023220703A1 (enExample) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| DK3294770T4 (da) | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
| EP3303632B2 (en) | 2015-05-29 | 2023-05-10 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| US12281118B2 (en) * | 2018-11-07 | 2025-04-22 | Shanghai Ringene Biopharma Co., Ltd. | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use |
| EP4034539A1 (en) * | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
-
2023
- 2023-05-12 AU AU2023269154A patent/AU2023269154B2/en active Active
- 2023-05-12 WO PCT/US2023/066920 patent/WO2023220703A1/en not_active Ceased
- 2023-05-12 US US18/864,984 patent/US20250312339A1/en active Pending
- 2023-05-12 CN CN202380040108.0A patent/CN119183377A/zh active Pending
- 2023-05-12 CA CA3248752A patent/CA3248752A1/en active Pending
- 2023-05-12 TW TW112117719A patent/TW202408523A/zh unknown
- 2023-05-12 JP JP2024566593A patent/JP2025516649A/ja active Pending
- 2023-05-12 KR KR1020247040965A patent/KR20250012585A/ko active Pending
- 2023-05-12 AR ARP230101183A patent/AR129314A1/es unknown
- 2023-05-12 EP EP23729279.2A patent/EP4522173A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579465B2 (ja) | 頭頸部癌の治療のためのｅｇｆｒ阻害剤 | |
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| CN108024541B (zh) | 用于治疗癌症的方法 | |
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| JP2012522837A5 (enExample) | ||
| JP2024530189A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2024540044A5 (enExample) | ||
| JP2024521105A5 (enExample) | ||
| JP2023531090A5 (enExample) | ||
| JP2022547061A5 (enExample) | ||
| KR20210142614A (ko) | 암 치료를 위한 이아다뎀스타트 조합물 | |
| WO2024183818A1 (zh) | 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途 | |
| AU2019397560A1 (en) | Therapeutic combinations of orally administered Docetaxel and A P-gp inhibitor for the treatment of cancer | |
| JP2025521501A5 (enExample) | ||
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN108135878A (zh) | 卡巴他赛及其治疗癌症的用途 | |
| JP2023549605A5 (enExample) | ||
| WO2025056747A1 (en) | Combination of a wee1 inhibitor and a pkmyt1 inhibitor | |
| TW201944997A (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 |